HIGHLIGHTS
SUMMARY
Downregulation of Nrf2 activity enhanced chemotherapeutic drug sensitivity in Keap1 mutated HNSCC cells. To identify the mechanisms associated with Nrf2 pathway activation in HNSCC, the authors sequenced the Keap1 and Nrf2 genes and identified mutations in Nrf2 immunopositive tumors. Knockdown of Keap1 by siRNA in HNSCC cells demonstrated enhanced Nrf2 pathway activity, which led to enhanced transcriptional activity thereby rendering HNSCC cells resistant to chemotherapy. In the lung cancer cells, Keap1 mutations showed more resistance to etoposide and carboplatin than to Keap1 wild-type cells. In concordance with these previous results, the results demonstrated . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.